Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q2 2021 Earnings Presentation
19 slides from Abcellera Biologics's earnings presentation, Aug 12, 2021
Slide 1: Q2 2021 Business Update
Q2 2021 Business Update AUG 12, 2021
Slide 2: Disclaimer
DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently
Slide 3: Q2 2021 Business Update Summary
138 6 Q2 2021. BUSINESS UPDATE SUMMARY. STRONG GROWTH OF CORE BUSINESS $792.6M 19 3 $65M NEW programs under contract NEW programs started MOLECULES entered clinical testing cumulative programs under contract in accounts receivable (AR) + accrued AR in cash & cash equivalents
Slide 4: Antibodies for Covid-19
2 antibodies for Covid-19 US shipments of bamlanivimab together with etesevimab halted in June because of the prevalence of resistant variants at the time (Gamma and Beta). Effective against Delta variant* bebtelovimab Effective against variants of concern, including the Delta variant* Currently in
Slide 5: Diverse portfolio that already covers most therapeutic areas
DIVERSE PORTFOLIO THAT ALREADY COVERS most therapeutic areas 138 PROGRAMS UNDER CONTRACT Q2 2021 BUSINESS UPDATE 5 therapeutic area KNOWN therapeutic area TBD
Slide 6: Unlock new targets
Q2 2021 BUSINESS UPDATE 6 UNLOCK NEW TARGETS 72% 28% Our partners look to us to unlock new targets across a range of target types. For targets that have been selected by our partners, a third include challenging, high-value targets: STANDARD targets DIFFICULT targets multi-pass transmembrane targets
Slide 7: Empower new modalities for next-gen therapies
Empower NEW modalities for next-gen therapies 7 Our platform is an operating system designed to support many next-gen modalities, including: Q2 2021 BUSINESS UPDATE
Slide 8: PUCs with downstream participation
115 PUCs with downstream participation Our Programs Under Contract with downstream participation span the entire spectrum of drug development firms: Q2 2021 BUSINESS UPDATE 8 40 PROGRAMS 24 PROGRAMS 5 PROGRAMS private & small cap biotech 46 PROGRAMS mid & large cap biotech global pharma other indust
Slide 9: Forward integration to accelerate drug development
FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT 9 TECH STACK PARTNER DEVELOPMENT Preclinical Phase 1 Antibody Discovery Phase 2 Phase 3 & Approval Expansion into GMP / CMC manufacturing: Q2 2021 BUSINESS UPDATE ABCELLERA DEVELOPMENT COMMERCIAL SALE
Slide 10: Create & capture value with deeper positions
Create & capture value with deeper positions Diverse deal structures provide the opportunity to deepen our position in successful molecules: 10 Q2 2021 BUSINESS UPDATE Royalties & Milestones Option to Invest Equity / Equity-like
Slide 11: Centralize innovation to make drug discovery faster
11 Centralize innovation to make drug discovery faster, more efficient & more cost effective. Q2 2021 BUSINESS UPDATE
Slide 12: Q2 2021 Financials update
Q2 2021 Financials update
Slide 13: Partnership business growth shows great strength in 1H 2021
Partnership business growth shows great strength in 1H 2021. 13 Q2 2021 BUSINESS UPDATE FINANCIALS Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results. Discovery Partners Programs Under Contract Program Starts # of Cumula
Slide 14: Four molecules in the clinic, over a dozen in preclinical development
Four molecules in the clinic, over a dozen in preclinical development. 14 Q2 2021 BUSINESS UPDATE FINANCIALS
Slide 15: $27.6M revenue driven by COVID-19 program
$27.6M revenue driven by COVID-19 program. 15 Q2 2021 BUSINESS UPDATE FINANCIALS Revenue USD $5.2M $3.0M $27.6M $1.0M $8.2M $21.2M $0.3M $11.2M Q2 2020 Q2 2021 +2.5X Note associated $3.6M royalty fee COVID-19 discovery program strong in Q2 2020
Slide 16: Operating expenses reflect continued strengthening of the platform
Operating expenses reflect continued strengthening of the platform. 16 Q2 2021 BUSINESS UPDATE FINANCIALS Q2 2021 $11.2M $1.5M Q2 2020 RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN $15.0M $9.1M $1.3M $0.5M Operating Expenses USD Q2 2021 Q2 2020 Q2 2021 Q2 2020
Slide 17: Net earnings (loss)
NET EARNINGS (LOSS) 17 Q2 2021 BUSINESS UPDATE FINANCIALS Net loss of $2.3M: Equivalent to ($0.01) per share (basic & diluted). EARNINGS (LOSS) PER SHARE: BASIC & DILUTED $6.7M ($2.3M) Q2 2021 Q2 2020 Q2 2020 Q2 2021 Earnings / Loss USD $0.03 ($0.01)
Slide 18: Operations results financed investments in H1 and strengthened liquidity
Operations results financed investments in H1 and further strengthened liquidity. 18 Q2 2021 BUSINESS UPDATE FINANCIALS Cash Flows USD $594.1M $267.2M $792.6M ($0.7M) ($6.6M) Additionally, $65M AR + accrued AR balance at quarter end $20.5M ($61.5M) $33.0M
Slide 19: Thank You
19 Thank You Q2 2021 BUSINESS UPDATE